Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany.
Department for Infection Control and Infectious Diseases, University Hospital Regensburg, Regensburg, Germany.
Infection. 2021 Aug;49(4):739-746. doi: 10.1007/s15010-021-01598-6. Epub 2021 Mar 10.
To follow serological immune responses of front-line healthcare workers after PCR-confirmed COVID-19 for a mean of 30 weeks, describe the time-course of SARS-CoV-2 spike protein-specific IgG, IgA and IgM levels and to identify associations of the immune response with symptoms, demographic parameters and severity of disease.
Anti-SARS-CoV-2 S protein-specific IgG, IgA and IgM antibodies were measured at three time points during the 30-week follow-up. COVID-19-specific symptoms were assessed with standardized questionnaires.
95% of the participants mounted an IgG response with only modest decline after week 12. IgG-type antibodies were still detectable in almost 90% of the subjects at 30 weeks. IgA and IgM responses were less robust and antibody titers decreased more rapidly. At 30 weeks, only 25% still had detectable IgA-type and none had IgM-type antibodies. Higher age and higher disease severity were independently associated with higher IgG antibody levels, albeit with wide variations.
Serological immune responses after COVID-19 show considerable inter-individual variability, but show an association with increasing age and higher severity of disease. IgG-type anti-SARS-CoV-2 antibodies remain positive in 90% of the individuals 30 weeks after onset of symptoms.
对经 PCR 确诊的 COVID-19 一线医护人员进行为期 30 周的血清学免疫反应随访,描述 SARS-CoV-2 刺突蛋白特异性 IgG、IgA 和 IgM 水平的时间过程,并确定免疫反应与症状、人口统计学参数和疾病严重程度的相关性。
在 30 周的随访期间,在三个时间点测量抗 SARS-CoV-2 S 蛋白特异性 IgG、IgA 和 IgM 抗体。使用标准化问卷评估 COVID-19 特异性症状。
95%的参与者产生了 IgG 反应,在第 12 周后仅有适度下降。在 30 周时,几乎 90%的受试者仍可检测到 IgG 型抗体。IgA 和 IgM 反应较弱,抗体滴度下降较快。在 30 周时,只有 25%的人仍可检测到 IgA 型抗体,没有人可检测到 IgM 型抗体。较高的年龄和较高的疾病严重程度与较高的 IgG 抗体水平独立相关,但存在较大差异。
COVID-19 后的血清学免疫反应表现出相当大的个体间变异性,但与年龄增长和疾病严重程度增加相关。在症状出现 30 周后,90%的个体仍可检测到 IgG 型抗 SARS-CoV-2 抗体。